Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

guideSkin Bridging regulatory science and innovation for dermal generics and advanced skin therapies

Coordinator
Eberhard Karls Universitaet Tuebingen, Germany
Runs
1 October 2026 to 30 September 2030
Status
Running
EU funding
€4.6m
Total cost
—
Partners
19 organisations in 8 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101310254

What the project is doing

In the project's own words, from its summary on CORDIS.

Skin diseases affect 900 million people worldwide and impose major physical, psychological, social and emotional burdens, making cutaneous drug products essential to public health.guideSkin is an Industrial Doctorate training 15 doctoral candidates to transform the development, evaluation and regulatory approval of cutaneous drug products in line with the new EMA Guideline on Quality and Equivalence of Cutaneous Products (effective 2025).

The guideline enables bioequivalence-based approval of dermal generics but requires advanced analytical and in vitro methods that many companies and regulators are not yet equipped to apply, causing delays in market entry, reduced innovation and a shortage of specialists able to interpret complex formulation and skin-interaction data.guideSkin brings together six European universities with key pharma manufacturers and technology-driven industry and SMEs.

We will develop a practical, science-based framework for formulation characterisation; advance key permeation-kinetics methods incl. confocal Raman spectroscopy (CRS), physiologically based pharmacokinetic (PBPK) modelling and AI-enabled prediction; and establish quality-evaluation strategies for innovative products such as microneedle array patches (MAPs) and nano-enabled formulations. Through long-term industrial secondments, interdisciplinary coursework, transferable-skills training and hands-on work in advanced facilities, DCs will gain expertise spanning pharmaceutical technology, spectroscopy, modelling, data and regulatory science.

We will deliver validated test protocols, decision trees and computational tools that support regulatory submissions and efficient product development.guideSkin will strengthen Europe’s innovation capacity and enable faster approval of high-quality dermal medicines and generics. Our graduates will be highly employable specialists able to shape future regulatory frameworks and drive competitiveness in Europe’s pharma and skin-health sectors.

Topics

Who is involved

OrganisationCityCountryRole
Eberhard Karls Universitaet TuebingenTuebingenGermanyCoordinator
Accelopment Schweiz AGZurichSwitzerlandAssociatedpartner
Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V.MainzGermanyAssociatedpartner
Dermapharm Holding SEGrünwaldGermanyAssociatedpartner
Esqlabs GmbHSaterlandGermanyAssociatedpartner
LTS Lohmann Therapie-Systeme AGAndernachGermanyAssociatedpartner
RaDes GmbHHamburgGermanyAssociatedpartner
proderm GmbHSchenefeldGermanyAssociatedpartner
Gie Lvmh RechercheSaint Jean De BrayeFranceAssociatedpartner
Universite Paris-SaclayGif-Sur-YvetteFranceParticipant
University College Cork - National University of Ireland, CorkCorkIrelandParticipant
Riverd International BVRotterdamNetherlandsAssociatedpartner
Tiofarma BVOud BeijerlandNetherlandsAssociatedpartner
Faculdade de Farmácia da Universidade de LisboaLisboaPortugalParticipant
Phardevelopment Trials, ldaColaresPortugalAssociatedpartner
Farmaceutski Fakultet Univerziteta U BeograduBelgradeSerbiaParticipant
Galenika a.d.BeogradSerbiaAssociatedpartner
Unilever U.k. Central Resources LimitedLondonUnited KingdomAssociatedpartner
University of SurreyGuildfordUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI